logo

IDYA

IDEAYA Biosciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 1
consensus rating "Buy"
ample liquidity
Net Income Plunges
EPS Beats Expectation

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About IDYA

Ideaya Biosciences, Inc.

A company that developing oncology therapies for the treatment of cancer using molecular diagnostics

Biological Technology
Invalid Date
05/23/2019
NASDAQ Stock Exchange
131
12-31
Common stock
7000 Shoreline Court, Suite 350, South San Francisco, California 94080
--
IDEAYA Biosciences, Inc., headquartered in South San Francisco, California, was incorporated in Delaware in June 2015. The company is an oncology-focused precision medicine company dedicated to discovering and developing targeted therapies for patient populations selected using molecular diagnostics. Their approach combines the broad ability to identify and validate translated biomarkers with small molecule drug discovery to select patient populations most likely to benefit from the targeted therapies they are developing. They are applying these capabilities to a variety of precision medicine, including direct targeting of carcinogenic pathways and synthetic lethality, which represents an emerging class of precision medicine targets.

Company Financials

EPS

IDYA has released its 2025 Q1 earnings. EPS was reported at -0.82, versus the expected -0.69, missing expectations. The chart below visualizes how IDYA has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime